Patents by Inventor Shiyang Pan

Shiyang Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Concrete crack repair material based on nano materials and its preparation method
    Patent number: 11981604
    Abstract: A concrete crack repair material based on nano materials includes raw materials as follows: seaweed, sulphoaluminate cement, natural sand, nano-silica fume, calcium formate, fly ash, anhydrous calcium sulphoaluminate, a polyester fiber, a water reducing agent, a corrosion inhibitor and water. By reasonably selecting the raw materials of the concrete crack repair material and making a reasonable ratio of the raw materials, the concrete crack repair material is obtained with excellent performance such as good compressive strength, bending strength and bond strength, and excellent impermeability and frost resistance. The concrete crack repair material can be used for the concrete crack repair in the marine environment, which has very important application values.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: May 14, 2024
    Assignee: NingboTech University
    Inventors: Chonggen Pan, Yu Hu, Shiyang Qu, Jiawei Zang
  • Anti-pancreatic cancer monoclonal antibody and use thereof
    Patent number: 10444237
    Abstract: A hybridoma cell line NM002-1 secreting an anti-human pancreatic cancer monoclonal antibody and deposited under CCTCC Accession NO: C201173. Also, an anti-human pancreatic cancer monoclonal antibody NJ002-1 secreted by the hybridoma cell line NM002-1 and use thereof.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 15, 2019
    Assignee: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Yue Pan, Shiyang Pan, Jian Xu
  • ANTI-PANCREATIC CANCER MONOCLONAL ANTIBODY AND USE THEREOF
    Publication number: 20180224457
    Abstract: A hybridoma cell line NM002-1 secreting an anti-human pancreatic cancer monoclonal antibody and deposited under CCTCC Accession NO: C201173. Also, an anti-human pancreatic cancer monoclonal antibody NJ002-1 secreted by the hybridoma cell line NM002-1 and use thereof.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 9, 2018
    Applicant: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Yue PAN, Shiyang PAN, Jian XU
  • Monoclonal antibody against human non-small cell lung carcinoma and use thereof
    Patent number: 8911727
    Abstract: The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: December 16, 2014
    Inventors: Shiyang Pan, Peijun Huang, Fang Wang